Showing 2441-2450 of 6036 results for "".
- FDA Issues Third Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalaphttps://modernod.com/news/fda-issues-third-complete-response-letter-to-aldeyra-therapeutics-for-dry-eye-drug-reproxalap/2486097/In another setback for Aldeyra Therapeutics, the FDA issued a third Complete Response Letter (CRL) regarding its new drug application (NDA) for investigational dry eye treatment reproxalap. In the letter, the FDA stated that th
- Study Links Vitamin D Deficiency to Higher Risk of Dry Eye Diseasehttps://modernod.com/news/study-links-vitamin-d-deficiency-to-higher-risk-of-dry-eye-disease/2486076/Key Takeaways A large retrospective cohort study found that adults with vitamin D deficiency had a significantly higher risk of developing dry eye
- New Research Highlights Opticians’ Key Role in Contact Lens Success, Strong Patient Trusthttps://modernod.com/news/new-research-highlights-opticians-key-role-in-contact-lens-success-strong-patient-trust/2486039/Key Takeaways 89% of contact lens wearers say
- Global Study Examines Orthokeratology Lenses and Childhood Myopia Progressionhttps://modernod.com/news/global-study-examines-orthokeratology-lenses-and-childhood-myopia-progression/2485610/A new international meta-analysis has found that orthokeratology lenses can significantly slow the progression of myopia in children, offering further evidence that the approach may play an important role in addressing the growing global myopia epidemic.
- Contact Lens Institute Names 17 Eye Care Leaders as 2026 Visionarieshttps://modernod.com/news/contact-lens-institute-names-17-eye-care-leaders-as-2026-visionaries/2485504/Key Takeaways Contact Lens Institute named 17 U.S. and Canadian eye care professionals as 2026 Visionaries
- Newton and ABB Labs Enter Partnership to Expand Access to Lens Portfolio in UShttps://modernod.com/news/newton-and-abb-labs-enter-partnership-to-expand-access-to-lens-portfolio-in-us/2485363/Newton announced that it has selected ABB Labs, an independent optical laboratory network, as a strategic laboratory partner. The collaboration aims to expand access to Newton’s lens portfolio across the United States. Accordi
- CooperVision to Launch of MyDay MiSight 1 Day Contact Lenses in Europehttps://modernod.com/news/coopervision-to-launch-of-myday-misight-1-day-contact-lenses-in-europe/2485287/CooperVision announced the upcoming launch of MyDay MiSight 1 day contact lenses in the UK and select European and surrounding markets. The new daily disposable soft contact lens combines MiSight 1 day ActivControl Technology,
- Celularity Enters Strategic Partnership with DefEYE to Advance Regenerative Therapies in Eye Carehttps://modernod.com/news/celularity-enters-strategic-partnership-with-defeye-to-advance-regenerative-therapies-in-eye-care/2484300/Celularity announced a strategic partnership with DefEYE, a newly established ophthalmic product and technology company. Under the terms of the agreement, Celularity has executed an exclusive license and pricing arrangement with DefEYE, following Celularity&rs
- The Vision Council Urges Commerce Department to Exclude Optical Products from Potential Tariffshttps://modernod.com/news/the-vision-council-urges-commerce-department-to-exclude-optical-products-from-potential-tariffs/2484295/The Vision Council has submitted formal comments to the US Department of Commerce opposing potential new tariffs that could affect essential optical products and equipment. The comments respond to two ongoing Section 2
- Regeneron Delays Regulatory Submission for Eylea HD Pre-Filled Syringe After CRLhttps://modernod.com/news/regeneron-delays-regulatory-submission-for-eylea-hd-pre-filled-syringe-after-crl/2484294/In its third quarters earnings filing, Regeneron said it received another complete response letter (CRL) from the FDA for its pre-filled syringe supplemental BLA (sBLA) for Eylea HD (aflibercept injection 8 mg). The sole approvability issue cited in the CRL relates to unresolved inspection findin